Nexstim Plc announced having received an order for two NBS 6 systems from a distributor company. Nexstim released the NBS 6 system earlier in 2023 in the EU and the United States. Developed in collaboration with Nexstim?s customers, the NBS 6 system makes the company?s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before.

The NBS 6 system is currently approved for the treatment of major depressive disorder (MDD) in the United States and EU as well as for the treatment of chronic neuropathic pain in the EU.